Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Sumatriptan and Rimegepant for Treating Nitroglycerin-Induced Headaches in Patients with Episodic Migraine

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial focuses on studying migraine, a common type of headache that can cause severe pain and other symptoms. The study will test two treatments: Sumatriptan and Rimegepant. These medications are used to relieve migraine symptoms. The trial will also involve the use of nitroglycerin, a substance that can induce headaches, to better understand how these treatments work during a migraine attack.

The purpose of the study is to observe changes in certain biochemical markers in the blood and saliva during a migraine attack and after treatment with Sumatriptan and Rimegepant. Participants will receive either Sumatriptan or Rimegepant during the trial, and their response to these treatments will be monitored. The study will help determine how these medications affect the levels of specific markers in the body, which could provide insights into their effectiveness in treating migraines.

Participants will be involved in a randomized cross-over trial, meaning they will receive both treatments at different times. The study will track the evolution of biochemical markers at four different points: before the migraine starts, at the beginning of the migraine, at the peak of the migraine, and two hours after treatment. This approach will help researchers understand the relationship between these markers and the response to migraine treatments.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be informed about the trial's purpose and procedures. You will be asked to sign an informed consent form, confirming your understanding and agreement to participate.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm your eligibility. This includes verifying your age, migraine diagnosis, and frequency of headaches.

  3. Step 3

    Inducing headache

    You will receive a medication called glyceryl trinitrate intravenously to induce a headache. This is part of the study to understand how migraines develop and respond to treatment.

  4. Step 4

    Treatment phase

    During the headache, you will be randomly assigned to receive either sumatriptan or rimegepant orally. These medications are used to treat migraines.

    Sumatriptan is typically taken as a single dose, while rimegepant is also taken as a single dose. The exact dosage will be provided by the study team.

  5. Step 5

    Monitoring and sample collection

    Your response to the treatment will be monitored. Blood and saliva samples will be collected at four different times: before the headache starts, at the beginning of the headache, at the peak of the headache, and two hours after taking the migraine treatment.

    These samples will help measure levels of certain substances in your body that are related to migraines.

  6. Step 6

    Cross-over phase

    After a period, you will switch to the other medication (either sumatriptan or rimegepant) and repeat the treatment and monitoring process. This allows for comparison of the two treatments.

  7. Step 7

    Completion of study

    Once all phases are completed, your participation in the study will end. You will receive information about the study's findings and any relevant health information.

Who can join the trial?

4 criteria

  • Adults between 18 and 60 years old.
  • Diagnosis of migraine, with or without aura (an aura is a visual or sensory disturbance that can occur before a migraine), according to the International Classification of Headache Disorders, 3rd edition.
  • Experience headaches less than 10 days per month.
  • Must sign the Informed Consent Form (a document that explains the study and any potential risks, which you agree to by signing).

Who cannot join the trial?

8 criteria

  • Patients who are not experiencing migraine attacks.
  • Patients who are not within the specified age range for the study.
  • Patients who are not willing to comply with the study procedures.
  • Patients who have any medical condition that the study doctors believe would make it unsafe for them to participate.
  • Patients who are currently participating in another clinical trial.
  • Patients who have a history of allergic reactions to the study medications, Sumatriptan or Rimegepant.
  • Patients who are pregnant or breastfeeding.
  • Patients who have used certain medications that might interfere with the study results.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Sumatriptan

    is a medication used to treat migraine headaches. It works by narrowing blood vessels around the brain and reducing substances in the body that can trigger headache pain, nausea, sensitivity to light and sound, and other migraine symptoms. In this trial, Sumatriptan is being tested to see how well it can relieve headaches that are artificially induced by a substance called nitroglycerin in people who suffer from episodic migraines.

  • Rimegepant

    is another medication used to treat migraine headaches. It works differently from Sumatriptan by blocking a protein in the brain that is involved in the development of migraine pain. This trial is examining how effective Rimegepant is in treating headaches caused by nitroglycerin in people with episodic migraines, and how it compares to Sumatriptan in terms of relief and changes in certain markers in the blood and saliva.

What is already known about the treatment

  • Sumatriptan

    Sumatriptan is a medication administered orally or via injection, commonly used to treat migraines. It is well-established in medical literature as an effective treatment for acute migraine attacks. The main therapeutic indication for Sumatriptan is the relief of migraine symptoms, including headache, nausea, and sensitivity to light and sound. At the molecular level, Sumatriptan works by stimulating serotonin receptors in the brain, which helps to reduce inflammation and constrict blood vessels, thereby alleviating migraine symptoms. It is classified pharmacologically as a selective serotonin receptor agonist.

  • Rimegepant

    Rimegepant is an oral medication used to treat migraines, and it is gaining recognition in medical literature as a promising option for acute migraine relief. The primary therapeutic indication for Rimegepant is the treatment of migraine attacks, providing relief from headache and associated symptoms. Rimegepant works by blocking the activity of a protein called CGRP, which is involved in the transmission of pain and inflammation during a migraine. It belongs to the pharmacological class of CGRP receptor antagonists.

Investigated diseases

Migraine – Migraine is a neurological condition characterized by intense, throbbing headaches, often on one side of the head. These headaches can be accompanied by nausea, vomiting, and sensitivity to light and sound. Migraine attacks can last from a few hours to several days and may occur with varying frequency. Some individuals experience warning symptoms, known as aura, before the onset of a migraine. The exact cause of migraines is not fully understood, but they are believed to involve changes in brain chemicals and nerve pathways. Triggers for migraines can include stress, certain foods, hormonal changes, and environmental factors.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-519770-38-00Protocol codeMAMBO-IIEstimated enrolment24 patientsSponsorFundacio Hospital Universitari Vall D’Hebron Institut De Recerca

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).